• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES GORE VIABAHN® ENDOPROSTHESIS - 3; NIP

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES GORE VIABAHN® ENDOPROSTHESIS - 3; NIP Back to Search Results
Catalog Number PAC101002E
Device Problem Difficult or Delayed Activation (2577)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 03/29/2019
Event Type  malfunction  
Manufacturer Narrative
(b)(4).
 
Event Description
On (b)(6) 2019, the patient underwent endovascular treatment of a femoral-popliteal aneurysm using two gore viabahn® endoprostheses.The first viabahn® device (5mm x 15cm, lot number unknown) was implanted distally with no issues.It was intended to implant a second viabahn® device (10mm x 10cm, lot number 19946750) proximally with some overlap.After initiating the deployment of the second viabahn® device it deployed approximately 3cm when big resistance was experienced while pulling the deployment knob.The deployment line got stock temporarily, and by the second harder pull the viabahn® device fully deployed but it was shortened by 2-3cm.It was suspected that the deployment line might got stuck between the viabahn® devices.It was reported that when removing the delivery system from the patient a short piece of red colored line was protruding from the access site.The physician manually pulled the line and removed it from the patient.It extended to approximately 30cm.The patient is doing well.It was reported that the treatment planning included a long sealing zone.Therefore no endoleak was seen despite the second viabahn® device was shortened.The result was described to be perfect.
 
Event Description
On (b)(6) 2019 the patient underwent endovascular treatment of a femoral-popliteal aneurysm using two gore viabahn® endoprostheses.The first viabahn® device (9 mm x 15 cm, lot number 20317150) was implanted distally with no issues.It was intended to implant a second viabahn® device (10 mm x 10 cm, lot number 19946750) proximally with some overlap.After initiating the deployment of the second viabahn® device it deployed approximately 3 cm when big resistance was experienced while pulling the deployment knob.The deployment line got stock temporarily, and by the second harder pull the viabahn® device fully deployed but it was shortened by 2-3cm.It was suspected that the deployment line might got stuck between the viabahn® devices.It was reported that when removing the delivery system from the patient a short piece of red colored line was protruding from the access site.The physician manually pulled the line and removed it from the patient.It extended to approximately 30 cm.The patient is doing well.It was reported that the treatment planning included a long sealing zone.Therefore no endoleak was seen despite the second viabahn® device was shortened.The result was described to be perfect.
 
Manufacturer Narrative
Added patient identifier; updated event description.Code-4116: the device remains implanted in the patient.The delivery catheter was returned for investigation.During investigation of the delivery catheter the following observations were made: the dual lumen was kinked 8 cm, 45 cm, 76 cm, and 111 cm from the hub.The remainder of the device was unremarkable.Engineering evaluation conclusion is inconclusive as it relates to the event description.Based on the device examination performed, no manufacturing anomalies were identified.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE VIABAHN® ENDOPROSTHESIS - 3
Type of Device
NIP
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
MDR Report Key8527440
MDR Text Key142491143
Report Number2017233-2019-00259
Device Sequence Number1
Product Code PFV
Combination Product (y/n)N
PMA/PMN Number
P130006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Type of Report Initial,Followup
Report Date 04/29/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date07/15/2021
Device Catalogue NumberPAC101002E
Device Lot Number19946750
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer04/15/2019
Was the Report Sent to FDA? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received04/18/2019
Supplement Dates Manufacturer ReceivedNot provided
Supplement Dates FDA Received05/27/2019
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
-
-